In the last 12 hours, coverage in the Uzbekistan health space is dominated by health-system governance and access reforms alongside a few items that touch the broader social environment. The most concrete health-related development is a presidentially signed resolution to improve medical service quality, setting unified requirements for medical organizations regardless of ownership and outlining a phased transition toward international licensing/accreditation standards, including a move of licensing functions to a dedicated “Center for Licensing and Accreditation of Medical Organizations” from July 1, 2026, plus plans for unified digital monitoring and accreditation standards. In parallel, Uzbekistan is also reported to be expanding free medicine coverage from 2027, with the number of free medicines for polyclinic patients rising from 28 to 69 items, delivered via electronic prescriptions through participating pharmacies under the state health insurance system, with nationwide rollout by end-2026.
The same 12-hour window also includes institutional reshaping in healthcare leadership: articles report that Uzbekistan’s Ministry of Health has undergone a leadership reshuffle, including the appointment of Eldor Odilov as Health Minister and new deputy appointments, with one portfolio specifically assigned to compliance and internal anti-corruption control. While these items are not “clinical” news, they are significant for health policy implementation because they indicate administrative capacity and oversight changes. Outside the health sector, the period also features regulatory and public-safety reporting (e.g., draft rules on outdoor signs), but the evidence provided does not directly connect those to healthcare outcomes.
From 12 to 24 hours ago, the health-related thread continues with private-sector participation and pharmaceutical governance. Uzbekistan is reported to be expanding powers for non-state medical institutions, including allowing private accredited providers to perform organ and tissue transplants (from May 1, 2027) and enabling private organizations to treat patients funded by the state budget under compulsory health insurance across licensed areas, with reimbursement based on unified base prices. There is also evidence of pharmaceutical-sector oversight tightening: the Anti-Corruption Agency is described as identifying systemic shortcomings in medicine registration/certification/licensing processes in the Dok-1 Max case, pointing to transparency and digitalization gaps and issues in the expert council structure that could create conflict-of-interest risks.
Overall, the most recent evidence is health-policy heavy (quality standards, free medicines, private-sector transplant authorization, and leadership/anti-corruption structures), suggesting a coordinated push to modernize regulation and access rather than a single isolated event. However, the provided dataset is also broad and includes many non-health headlines (diplomacy, migration, economic policy, and general news), so conclusions about “impact” on population health should be treated cautiously until more outcome-focused reporting appears.